Hexagon Nutrition IPO Review: Strong Margins, Global Exports, But Is the Valuation Fair?

Chances are you have never heard of Hexagon Nutrition Limited. But there is a good chance you have indirectly consumed its products. When a food brand adds vitamins to biscuits or a UN health program distributes nutrient-rich therapeutic food to malnourished children, Hexagon could be working quietly behind the scenes.

The company is now coming up with a ₹138.87 crore IPO, valuing the business at around ₹553 crore at the upper end of the price band. However, investors should note that this is a pure OFS (Offer for Sale), meaning the company itself will not receive any fresh capital from the issue.

So the key question is: Does Hexagon's improving business performance, niche positioning, and industry opportunity justify the valuation despite the IPO offering no direct growth capital to the company?

In the sections below, we break down the business model, industry opportunity, strengths, risks, and valuation to understand whether the IPO deserves a closer look.

Key Details at a Glance

Disclaimer: GMP figures are unofficial, unregulated market indicators based on speculative trading before the IPO lists. They do not guarantee listing price performance and should not be the basis of any investment decision.

What Does Hexagon Nutrition Actually Do?

Think about the last time you bought a health drink, fortified biscuit, or protein supplement. The brand name was on the packet, but a company like Hexagon may have made the actual nutrients inside. In simple words, Hexagon Nutrition works behind the scenes, supplying nutrition ingredients and products used by food brands, healthcare companies, and global health agencies.

The company operates across three main businesses.

1. The "Invisible Vitamins" Business (Over 51% of Revenue)

This is Hexagon’s biggest business segment. Large food and beverage brands want to add vitamins and minerals to their products, but nutrients can affect taste, smell, or color. Hexagon solves this by creating customised nutrient blends, called premixes, that can be added without changing the final product experience.

Think of it like the company supplying the secret ingredient mix while the consumer only sees the final brand on the shelf.

2. Branded Health and Wellness Products

Hexagon also sells its own nutrition brands, including PENTASURE and OBESIGO, through pharmacies and online platforms. These products are recommended by over 20,000 healthcare professionals across India.

This segment is important because branded nutrition products generally earn better profit margins than the company’s B2B premix business.

3. Therapeutic Foods for Child Malnutrition

The company also manufactures Ready-to-Use Therapeutic Food (RUTF), a nutrient-rich paste designed to treat severe acute child malnutrition. These products are supplied globally through long-term arrangements with various United Nations agencies, international health organizations, and government health ministries.

This business is growing rapidly, with therapeutic food revenue rising 146.88% in FY25, reflecting increasing global demand.

Hexagon currently operates three manufacturing plants in India and one in Uzbekistan, exports to over 75 countries, and distributes products through a large domestic and international network. This gives the company a meaningful global presence for its size.

Is the Industry Growing Fast Enough to Matter?

India’s nutrition and wellness market is currently valued at around ₹1,528 billion and is expected to grow to nearly ₹2,814 billion by 2030. That is a massive growth opportunity in a relatively short period.

The biggest reason is India’s unusual nutrition challenge at both ends. On one side, over 101 million diabetics and around 135 million obese individuals are driving demand for disease-management nutrition, supplements, and weight-control products. On the other side, malnutrition remains a serious issue, with 35.5% of children under five suffering from stunting. Government programs like POSHAN Abhiyaan are also increasing focus on nutritional access.

India’s elderly population is expected to reach 194 million by 2031, creating another long-term demand driver for healthcare and age-focused nutrition products.

However, industry growth alone does not guarantee success. Large players like Abbott Healthcare and Nestle India Limited have much bigger brands, distribution networks, and marketing strength. Rural markets also remain highly price-sensitive.

Still, Hexagon has built strong positions in customised premix manufacturing and UN therapeutic nutrition supply, where its scientific capabilities and approved-supplier status provide meaningful competitive advantages.

What Actually Makes This Company Strong?

Exports contribute around 55% of Hexagon’s total revenue, and the company sells products across more than 75 countries, supported by a manufacturing facility in Uzbekistan. Unlike many smaller Indian companies that depend heavily on domestic demand, Hexagon earns a meaningful share of revenue from multinational food companies and UN agencies globally. This international presence helps diversify the business and reduces dependence on any single market.

At the same time, the company is steadily improving the quality of its earnings by shifting from lower-margin bulk ingredients towards higher-margin branded and therapeutic nutrition products. Its branded disease nutrition segment grew 28.34% in FY25, while therapeutic foods surged 146.88%. As a result, raw material costs as a share of revenue declined from 60.43% to 55.56%, helping improve overall profitability.

Another important strength is the company’s integrated operating model. Unlike many nutrition businesses that outsource production, Hexagon manufactures key premix raw materials in-house with support from over 17 research professionals and three manufacturing plants in India. This setup helps the company maintain better quality control, develop products faster, and reduce dependence on third-party suppliers. It also creates a meaningful competitive advantage in customised premix manufacturing, where consistency and formulation expertise are critical for large global food brands.

What Are the Real Risks Investors Should Know?

Around 30% of Hexagon’s revenue comes from just five large institutional clients, including multinational food companies and global agencies. This creates customer concentration risk, where losing even one major client could meaningfully affect revenue and profitability. If large customers reduce orders, renegotiate pricing, or shift to competitors, the impact on the business could be significant. Investors should closely watch how the company diversifies its customer base over time.

Another important risk comes from the company’s global exposure. Since exports contribute nearly 55% of total revenue, Hexagon is heavily affected by currency fluctuations and international geopolitical developments. A stronger rupee can reduce export earnings in rupee terms, while disruptions in regions like West Asia can increase freight costs and delay deliveries. These are external factors that can pressure margins even when the core business remains stable.

The company also remains heavily dependent on China for raw materials. Around 58.38% of sourcing comes from China, along with additional dependence on Malaysia and Singapore. Since vitamins and micronutrients are highly specialised ingredients, any supply disruption, trade restriction, or price spike in these countries could directly increase costs and impact production. If alternative sourcing becomes necessary, margins may come under pressure due to higher procurement costs.

Valuation & Peer Comparison: Is the Asking Price Justified?

At IPO price of ₹45, Hexagon Nutrition is valued at around ₹553 crore. To judge whether this looks reasonable, it helps to compare the company with listed peers like Zydus Wellness Limited and Nestle India Limited.

The headline number here is the P/E ratio of 15.35x. In simple words, investors are paying ₹15.35 for every ₹1 of Hexagon’s earnings. Compared to Zydus Wellness at 46.22x and Nestle India at 88.86x, Hexagon appears meaningfully cheaper.

Of course, lower valuation does not automatically mean better value. Nestle and Zydus command premium valuations because of their stronger brands, larger scale, and long-established distribution networks. Hexagon remains a smaller niche player in comparison.

That said, some financial indicators look encouraging. The company’s ROCE of 17.1% is strong, especially against Zydus Wellness at 6.3%, showing reasonably efficient use of capital. EBITDA margins of 12.3% are decent for a business with highly customised manufacturing, while the debt-to-equity ratio of 0.14 keeps financial risk relatively low.

Overall, the IPO valuation does not appear overly aggressive for a company operating in a growing nutrition segment with improving profitability. However, investors should still factor in the pure OFS structure and risks around customer concentration and raw material dependence before taking a view.

Author's Take: Should You Apply?

Hexagon Nutrition is not the kind of company that grabs attention with flashy branding or explosive growth. Instead, it offers a relatively niche but globally integrated nutrition business with improving profitability and a reasonable valuation.

The positives are meaningful. Net profit has grown from ₹5.8 crore to ₹24.4 crore in two years, margins are improving, and debt remains low. The company also has strong positioning in customised premix manufacturing and UN therapeutic nutrition supply, supported by exports across 75+ countries. At 15.35x earnings, the valuation appears fairly moderate compared to listed peers.

At the same time, investors should not ignore the risks. This is a 100% OFS, meaning the company itself will not receive fresh capital from the IPO. The business also remains dependent on a small set of large clients, imported raw materials from China, and export-driven revenue, all of which create execution and operational risks.

Overall, Hexagon Nutrition looks like a cautiously interesting opportunity for long-term investors who understand smaller niche businesses and are comfortable with moderate risk.

For a seamless application process, visit the INDmoney IPO page.

Source: Hexagon Nutrition's RHP. This blog is intended purely for educational and informational purposes. It does not constitute investment advice, a solicitation to buy or sell, or a formal research report.